<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03912571</url>
  </required_header>
  <id_info>
    <org_study_id>12-00041</org_study_id>
    <nct_id>NCT03912571</nct_id>
  </id_info>
  <brief_title>Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment</brief_title>
  <official_title>Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the sleep patterns of subjects with or without
      sleep disturbances (insomnia, sleep apnea) and compare these findings with their previous
      FDG/PIB PET, structural MRI and brain blood flow scams performed during their participation
      in the Following studies 'Alzheimer's Disease Core Center (ADCC) Clinical Evaluation' (IRB:
      2942), MRI Progression Markers of Cognitive Decline in the Elderly' (IRB:09-0586), or
      'Imaging Neuro inflammation in Alzheimer's Disease with [11C] Arachidonic Acid (AA) and
      PET'(IRB: 10-00442).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2011</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased cerebral blood flow (CBF)</measure>
    <time_frame>1 Week</time_frame>
    <description>Measured by perfusion MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of vasoreactivity to CO2 (VRCO2)</measure>
    <time_frame>1 Week</time_frame>
    <description>subjects will breath through a respiratory tube and CO2 will be meaured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in cortical AB plaque burden</measure>
    <time_frame>1 Week</time_frame>
    <description>Measured by PIB PET</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Sleep Disorder</condition>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Cognition (NL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Structural 3T MRI</intervention_name>
    <description>measures of global and hippocampal atrophy)</description>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <arm_group_label>Normal Cognition (NL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI Based Perfusion Imaging</intervention_name>
    <description>brain blood flow</description>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <arm_group_label>Normal Cognition (NL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VR-CO2 MRI Scans</intervention_name>
    <description>reduced vaso reactivity to carbon dioxide</description>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
    <arm_group_label>Normal Cognition (NL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects will have participated in prior CBH studies and have agreed to an FDG,
             PIB and MRI scans.

        Exclusion Criteria:

          -  Diagnosis of sleep apnea and under treatment with a continuous positive airway
             pressure (CPAP) machine.

          -  Active depressive episode during the evaluation with a Geriatric Depression Scale
             score &gt;7 and/or a Clinical Global Impression scale for depression score &gt;4.

          -  Moderate Cognitive decline (GDS &gt;3).

          -  Severe primary or secondary insomnia except insomnia due to SDB.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Osorio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

